ChartMill · Sep 15, 2026
Discover which S&P500 stocks are making waves on Tuesday.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
NASDAQ · TMO
Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
$641.39
Up+$28.24 (+4.61%)
Updated Sep 16, 2026, 10:52 AM
SID Score
6.8/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 219.39B
- P/E ratio
- 33.3
- Dividend yield
- 0.33%
- 52-week range
- $435.27 – $647.00
- Volume
- 3.02M
- Avg. volume
- 2.05M
Price performance
TMO price history
1M range · 20 trading sessions · Daily adjusted prices
TMO closed at $641.39 after 20 trading sessions, up 8.89% for the selected period.
- Last close
- $641.39
- Period change
- +8.89%
- Period low
- $589.04
- Period high
- $641.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $615.47 | $641.97 | $613.95 | $641.39 | 3.02M |
| Sep 14, 2026 | $614.94 | $616.00 | $605.65 | $613.62 | 1.27M |
| Sep 11, 2026 | $609.96 | $615.24 | $606.15 | $609.82 | 1.79M |
| Sep 10, 2026 | $596.47 | $606.63 | $594.82 | $603.18 | 1.55M |
| Sep 9, 2026 | $601.93 | $609.51 | $597.31 | $605.69 | 1.96M |
| Sep 8, 2026 | $602.20 | $608.10 | $595.82 | $603.02 | 2.7M |
| Sep 4, 2026 | $608.58 | $615.74 | $605.525 | $613.78 | 1.23M |
| Sep 3, 2026 | $614.03 | $622.91 | $603.52 | $618.43 | 1.8M |
| Sep 2, 2026 | $601.63 | $614.5975 | $600.70 | $608.54 | 1.62M |
| Sep 1, 2026 | $619.00 | $621.00 | $599.52 | $600.50 | 1.39M |
| Aug 31, 2026 | $614.38 | $620.715 | $610.35 | $617.10 | 1.43M |
| Aug 28, 2026 | $626.58 | $630.00 | $617.45 | $622.18 | 1.02M |
| Aug 27, 2026 | $629.47 | $637.13 | $626.33 | $630.70 | 1.47M |
| Aug 26, 2026 | $622.23 | $636.06 | $622.23 | $633.71 | 1.84M |
| Aug 25, 2026 | $631.01 | $647.00 | $618.0303 | $628.15 | 1.54M |
| Aug 24, 2026 | $630.00 | $630.00 | $615.97 | $628.74 | 1.73M |
| Aug 21, 2026 | $626.48 | $629.51 | $616.27 | $629.27 | 1.56M |
| Aug 20, 2026 | $609.85 | $634.70 | $607.37 | $627.55 | 2.75M |
| Aug 19, 2026 | $595.11 | $620.475 | $594.995 | $613.54 | 2.51M |
| Aug 18, 2026 | $588.87 | $592.22 | $584.86 | $589.04 | 1.72M |
Latest TMO news
The latest Smart Investors Daily articles mentioning TMO.
Stock researchCompany · Overview
TMO research
Overview
Company profile and research snapshot.
Company profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $625.78
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | CLSA | Outperform | — |
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
| Jul 27, 2026 | Piper Sandler | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 15, 2026
Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028
In an interview with CNBC on Tuesday, Marc Casper said AI is helping drugmakers identify ineffective medicines quicker while also shortening the time to market for promising therapies.
Yahoo · Sep 15, 2026
High Content Screening Market Forecasts Growth from $3.37B (2026) to $6.58B by 2032, Profiling Thermo Fisher, Danaher, GE HealthCare & 27 Other Key Players
Opportunities center on AI-enabled imaging, lab automation, advanced 3D and patient-derived cell models, CRO partnerships, and expanding global life sciences research.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "High Content Screening Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global High Content Screening Market, projected to reach USD 3.37 billion in 2026 and USD 6.58 billion by 2032, representing a CAGR of 1
Yahoo · Sep 15, 2026
Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear
Mayo Clinic today announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific, the world leader in serving science, to help transform how the life sciences community understands the biological changes that occur as people move from health toward disease.
AI research layers
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares closed at $641.39, reflecting a single-session decline of approximately 1.05%, per SID market data. Despite the daily pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 9.03% over the past month and 35.39% over the trailing three months. On a twelve-month basis, TMO has appreciated 10.79%, underperforming broader market indices over the same period. Technical indicators show the stock trading well above both its 50-day moving average of $582.76 and its 200-day moving average of $527.68, representing premiums of roughly 10.1% and 21.6% respectively, according to Massive/Polygon data. The 14-day relative strength index sits at 55.7, suggesting neither overbought nor oversold conditions. TMO carries a beta of 0.902, indicating modestly lower volatility than the broader market. Average daily trading volume stands at approximately 2.05 million shares.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific currently commands a market capitalization of approximately $219.4 billion, positioning it among the largest companies in the Healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 33.30, reflecting a premium valuation relative to broader market averages, according to SEC filings. The price-to-book ratio stands at 4.29, indicating investors are paying a meaningful premium above the company's book value per share. The PEG ratio registers at an elevated 577.17, suggesting that the current earnings multiple is not well supported by near-term earnings growth expectations. Thermo Fisher offers a modest dividend yield of approximately 0.29%, positioning the stock as a growth-oriented holding rather than an income vehicle. Within the Healthcare sector, TMO's valuation metrics reflect the market's pricing of its diversified life sciences portfolio and long-term revenue durability, though the elevated PEG ratio warrants attention relative to growth assumptions.
Smart Money Activity for TMO
Thermo Fisher Scientific's composite smart money score stands at 54 out of 100, signaling a neutral overall reading, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, reflecting strong conviction from large fund managers as reported in 13F institutional filings. In contrast, insider activity paints a more cautious picture, scoring just 9.7 out of 25. According to SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, consisting of only 2 purchases versus 18 sales, indicating a pronounced imbalance toward insider dispositions. Dark pool activity registers at 8.5 out of 25, suggesting below-average accumulation in off-exchange venues. Congressional trading activity scores 11.2 out of 25, reflecting moderate legislative interest in the stock. The divergence between institutional enthusiasm and insider selling behavior represents a notable dynamic. While institutional holders maintain strong conviction, the elevated pace of insider selling over the recent quarter suggests corporate officers and directors have been actively reducing personal exposure.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific has delivered consecutive earnings beats in its most recent reporting periods, according to company earnings reports. In the most recently completed quarter, the company reported earnings per share of $6.03 against analyst estimates of $5.71, representing a positive surprise of $0.32, or approximately 5.6% above consensus expectations. The prior quarter similarly exceeded forecasts, with actual EPS of $5.44 versus the $5.23 estimate, a $0.21 upside surprise. Looking ahead, analyst estimates project EPS of $5.71 and $5.29 for the two upcoming quarters, per consensus analyst estimates. The next earnings report is anticipated on or around July 22, 2026. The consistent pattern of outperformance suggests management has maintained disciplined cost controls and operational execution. The sequential increase from $5.44 to $6.03 in reported EPS also reflects positive quarterly momentum in underlying business fundamentals across Thermo Fisher's diversified life sciences operations.
Wall Street Analyst Ratings for TMO
Wall Street coverage of Thermo Fisher Scientific reflects a moderately constructive consensus, per SID consensus data. The most recent initiation came from CLSA on September 3, 2026, assigning an Outperform rating, adding a fresh bullish voice to the coverage universe. Morgan Stanley maintained its Overweight rating on July 27, 2026, reaffirming confidence in the company's long-term positioning, according to Wall Street analyst reports. Barclays similarly reiterated an Overweight stance on July 24, 2026. Not all coverage is uniformly bullish, however. Piper Sandler maintained a Neutral rating on July 27, 2026, while RBC Capital held its Sector Perform rating on July 24, 2026. Among the five most recent analyst actions, three carry bullish-leaning designations while two remain at market-perform equivalents. No analyst within recent coverage has issued a bearish downgrade or underperform-equivalent rating. The absence of negative revisions following the latest earnings beat suggests the sell-side views TMO's fundamental trajectory as stable to improving.
